We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Agilent Signs Agreement to Acquire Stratagene

Agilent Signs Agreement to Acquire Stratagene

Agilent Signs Agreement to Acquire Stratagene

Agilent Signs Agreement to Acquire Stratagene

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent Signs Agreement to Acquire Stratagene"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agilent Technologies Inc. announced that it has signed a definitive agreement with Stratagene Corp. to acquire the developer, manufacturer and marketer of specialized life science research and diagnostic products.

Under the terms of the agreement, each share of Stratagene common stock will be converted into the right to receive a cash payment of $10.94. The acquisition is expected to be closed in approximately 90 days, subject to certain closing conditions.

Stratagene's products are used by scientists in academia, government research and industry in molecular biology, genomics, proteomics, drug discovery and toxicology. Stratagene's portfolio includes reagents for life science research and instruments. The company also offers a range of diagnostics products, including applications for allergy testing and urinalysis.

The acquisition of Stratagene is expected to broaden the customer base for both Agilent and Stratagene.

"We see Stratagene's technology, products and expertise as being highly complementary to Agilent's life sciences portfolio, enabling us to offer our customers more complete workflow solutions," said Nick Roelofs, vice president and general manager of Agilent's Life Sciences Solutions Unit.

"Stratagene has a strong R&D team as well as excellent presence in the important academic and government markets," Roelofs added.